Patent intelligence · US
US 8852936
Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive …
Patent details — US 8852936
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 7, 2014
- Expiration
- Oct 2, 2034
- Applicant
- Laurantis Pharma Oy
- Claims
- 28
- CPC classes
- A61K, A61K35/26, A61K35/36, A61K38/1866
Quick answer
US 8852936 (Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery) is held by Laurantis Pharma Oy. Status: granted. Granted Oct 7, 2014. Expires Oct 2, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Laurantis Pharma Oy
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K35/26, A61K35/36, A61K38/1866, A61K48/005, A61K48/0075
More from Laurantis Pharma Oy
Related pharmaceutical patents in our USPTO index.
-
US 11786503
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 11166936
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10874633
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10806716
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10688172
HPV particles and uses thereof
granted -
US 10596275
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10300150
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10179168
HPV particles and uses thereof
granted
Frequently asked questions
What is US patent 8852936?
US 8852936 (Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery) is held by Laurantis Pharma Oy. Status: granted. Granted Oct 7, 2014. Expires Oct 2, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8852936?
Laurantis Pharma Oy is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 8852936 expire?
Our index shows an expiration date of Oct 2, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.